UBS set a GBX 1,550 ($20.86) price target on GlaxoSmithKline (LON:GSK) in a research note issued to investors on Wednesday, www.boersen-zeitung.de reports. The brokerage currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the stock. reaffirmed a buy rating and issued a GBX 1,970 ($26.51) price target on shares of GlaxoSmithKline in a report on Wednesday, September 13th. Liberum Capital reaffirmed a buy rating and issued a GBX 1,900 ($25.57) price target on shares of GlaxoSmithKline in a report on Wednesday, August 30th. Jefferies Group decreased their price target on shares of GlaxoSmithKline from GBX 1,900 ($25.57) to GBX 1,750 ($23.55) and set a buy rating for the company in a report on Thursday, August 24th. Berenberg Bank reaffirmed a buy rating and issued a GBX 1,835 ($24.70) price target on shares of GlaxoSmithKline in a report on Tuesday, September 19th. Finally, Goldman Sachs Group reaffirmed a buy rating and issued a GBX 1,900 ($25.57) price target on shares of GlaxoSmithKline in a report on Tuesday, October 17th. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 1,562.86 ($21.03).

Shares of GlaxoSmithKline (GSK) opened at GBX 1,295 ($17.43) on Wednesday. GlaxoSmithKline has a 52-week low of GBX 1,270 ($17.09) and a 52-week high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last posted its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The business had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline had a net margin of 17.79% and a return on equity of 461.88%.

The company also recently declared a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.26) per share. The ex-dividend date is Thursday, November 9th. This represents a yield of 1.41%.

In related news, insider Simon Dingemans bought 1,076 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were acquired at an average price of GBX 1,527 ($20.55) per share, for a total transaction of £16,430.52 ($22,113.76). Also, insider Urs Rohner bought 473 shares of the company’s stock in a transaction dated Wednesday, October 25th. The stock was bought at an average price of GBX 1,518 ($20.43) per share, for a total transaction of £7,180.14 ($9,663.71). In the last 90 days, insiders have purchased 1,577 shares of company stock worth $2,400,086.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline (GSK) Given a GBX 1,550 Price Target at UBS” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/glaxosmithkline-gsk-given-a-gbx-1550-price-target-at-ubs/1769225.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.